The overall objectives of the Virology Core Laboratory are to provide ACTU investigators with quality-controlled laboratory services required for evaluation of clinical samples in the context of AIDS clinical treatment trials. this requires a well-organized, proficient HIV virology laboratory, a computerized specimen and data storage and retrieval system, and professional staff with expertise in HIV biology, molecular biology, and cell culture.
Specific aims of the UAB ACTU Virology Core Laboratory will be: (i) To provide protocol-mandated testing of standard virologic markers (HIV-1 culture, p24 antigen, and ELISA and Western blot antibody analysis) for Birmingham and regional ACTU facilities. (ii) To participate in ACTG development, testing, and validation of additional surrogate markers such as quantitative determinations of plasma and PBMC viremia, acidified serum p24 antigenemia, and PCR (polymerase chain reaction) amplified total and circular viral DNA. (iii) To provide state-of-the-art cell and tissue separation and cryopreservation for optimal storage of clinical specimens for subsequent analysis. These specimens will be used for studies of surrogate markers, viral drug resistance, and other parameters relevant to improved diagnosis and treatment of HIV-1 infection and its sequelae. (iv) To participate in ACTG and internal quality-control/quality assurance programs to ensure accurate and efficient processing, analysis, cataloging, and retrieval of clinical specimens for protocol-mandated testing and developmental research. Results from ongoing basic and clinical studies are presented to demonstrate that the Birmingham site has the scientific expertise and experience to accomplish the stated aims and to provide a leadership role within the framework of the ACTG in the development of improved surrogate markers. Capability is demonstrated to perform 10,000 HIV-1 cultures and 40,000 antigen and antibody tests per year based on current laboratory activity. Finally, a close, interactive working relationship is demonstrated between the professional staff of the existing HIV laboratory and clinical investigators currently directing ACTG and non-ACTG sponsored clinical studies at UAB.

Project Start
1997-01-01
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Lockman, Shahin; Hughes, Michael; Sawe, Fred et al. (2012) Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 9:e1001236
Ciaranello, Andrea L; Lockman, Shahin; Freedberg, Kenneth A et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25:479-92
Boltz, Valerie F; Zheng, Yu; Lockman, Shahin et al. (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 108:9202-7
Haas, David W; Koletar, Susan L; Laughlin, Laura et al. (2009) Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 50:290-3
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Twigg Iii, Homer L; Weiden, Michael; Valentine, Fred et al. (2008) Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 197:109-16
Kilby, J Michael; Lee, Ha Youn; Hazelwood, J Darren et al. (2008) Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 22:957-62
Riddler, Sharon A; Jiang, Hongyu; Tenorio, Allan et al. (2007) A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 12:531-41
Acosta, Edward P; Kendall, Michelle A; Gerber, John G et al. (2007) Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 51:3104-10

Showing the most recent 10 out of 71 publications